CA3087288A1 - Inhibitors of egfr and methods of use thereof - Google Patents
Inhibitors of egfr and methods of use thereof Download PDFInfo
- Publication number
- CA3087288A1 CA3087288A1 CA3087288A CA3087288A CA3087288A1 CA 3087288 A1 CA3087288 A1 CA 3087288A1 CA 3087288 A CA3087288 A CA 3087288A CA 3087288 A CA3087288 A CA 3087288A CA 3087288 A1 CA3087288 A1 CA 3087288A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- subject
- egfr
- compound
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862632819P | 2018-02-20 | 2018-02-20 | |
| US62/632,819 | 2018-02-20 | ||
| US201862744086P | 2018-10-10 | 2018-10-10 | |
| US62/744,086 | 2018-10-10 | ||
| PCT/US2019/018773 WO2019164948A1 (en) | 2018-02-20 | 2019-02-20 | Inhibitors of egfr and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3087288A1 true CA3087288A1 (en) | 2019-08-29 |
Family
ID=67687390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3087288A Pending CA3087288A1 (en) | 2018-02-20 | 2019-02-20 | Inhibitors of egfr and methods of use thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200390783A1 (https=) |
| EP (1) | EP3755690A4 (https=) |
| JP (1) | JP2021514400A (https=) |
| AU (1) | AU2019225806A1 (https=) |
| CA (1) | CA3087288A1 (https=) |
| WO (1) | WO2019164948A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11584746B2 (en) | 2018-02-20 | 2023-02-21 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
| CN119317636A (zh) * | 2023-03-07 | 2025-01-14 | 艾博生物科技(上海)有限公司 | 编码活化EGFR突变肽的免疫调节治疗性mRNA组合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040254159A1 (en) * | 2003-02-27 | 2004-12-16 | Hasvold Lisa A. | Heterocyclic kinase inhibitors |
| WO2006061126A2 (en) * | 2004-12-09 | 2006-06-15 | F. Hoffmann-La Roche Ag | Dibenzoxazepinone derivatives |
| WO2007056388A2 (en) * | 2005-11-07 | 2007-05-18 | The General Hospital Corporation | Compositions and methods for modulating poly (adp-ribose) polymerase activity |
| US20110028458A1 (en) * | 2008-04-11 | 2011-02-03 | Thallion Pharmaceuticals Inc. | Inhibition of cell migration by a farnesylated dibenzodiazepinone |
| JP5752601B2 (ja) * | 2008-12-08 | 2015-07-22 | ブイエム ファーマ エルエルシー | タンパク質受容体チロシンキナーゼ阻害薬の組成物 |
| EP3828185B1 (en) * | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| WO2012045194A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Benzodiazepinones as fak inhibitors for treatment of cancer |
| WO2014160430A1 (en) * | 2013-03-13 | 2014-10-02 | Georgetown University | Small molecule lrrk2 and erk5 inhibitors |
| US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
| WO2017024317A2 (en) * | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| KR20180132812A (ko) * | 2016-04-07 | 2018-12-12 | 다나-파버 캔서 인스티튜트 인크. | 피리미도-디아제피논 키나아제 스캐폴드 화합물 및 ｐｉ3ｋ-매개된 장애의 치료 방법 |
| CA3018429A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use |
| US11584746B2 (en) * | 2018-02-20 | 2023-02-21 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and methods of use thereof |
-
2019
- 2019-02-20 WO PCT/US2019/018773 patent/WO2019164948A1/en not_active Ceased
- 2019-02-20 CA CA3087288A patent/CA3087288A1/en active Pending
- 2019-02-20 EP EP19758285.1A patent/EP3755690A4/en not_active Withdrawn
- 2019-02-20 JP JP2020566548A patent/JP2021514400A/ja active Pending
- 2019-02-20 AU AU2019225806A patent/AU2019225806A1/en not_active Abandoned
- 2019-02-20 US US16/970,881 patent/US20200390783A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019164948A1 (en) | 2019-08-29 |
| JP2021514400A (ja) | 2021-06-10 |
| US20200390783A1 (en) | 2020-12-17 |
| EP3755690A4 (en) | 2021-10-27 |
| AU2019225806A1 (en) | 2020-07-16 |
| EP3755690A1 (en) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3087288A1 (en) | Inhibitors of egfr and methods of use thereof | |
| EP3892272B1 (en) | Bifunctional molecules for degradation of egfr and methods of use | |
| US12161649B2 (en) | Inhibitors of EGFR and methods of use thereof | |
| EP3317273B1 (en) | Inhibitors of egfr and methods of use thereof | |
| CA3087797A1 (en) | Pharmaceutical combinations of egfr inhibitors and methods of use thereof | |
| EP3755689B1 (en) | Inhibitors of egfr and methods of use thereof | |
| US20200377501A1 (en) | Degraders of egfr and methods of use thereof | |
| US20210077469A1 (en) | Pharmaceutical combinations of egfr inhibitors and methods of use thereof | |
| CA3088561A1 (en) | Degraders of egfr and methods of use thereof | |
| CA3087800A1 (en) | Pharmaceutical combinations of egfr inhibitors and methods of use thereof |